BioGeometry Announces Strategic Cooperation with Symary Biopharma for the Large Molecule Drug R&D

BioGeometry, a digital biology pioneer company that specializes in applying generative AI to protein design, and Symary Biopharma recently announced the official signing of a strategic cooperation agreement. Both parties will fully leverage their respective strengths in a comprehensive strategic collaboration within the field of large molecule pharmaceuticals, aiming to achieve breakthrough progress in antibody drug R&D through the application of AI technology.

According to the agreement, BioGeometry will provide Symary Biopharma with access to its antibody discovery models or the GeoBiologics generative AI antibody design platform, which Symary Biopharma will use to train and optimize with project data. Additionally, BioGeometry will offer specialized services such as antibody humanization, druglikeness analysis, and antibody optimization tailored to specific project needs, as well as taking charge of antibody protein engineering and optimization during the joint pipeline development of targets. Symary Biopharma will be responsible for the discovery, screening, and in vitro and in vivo pharmacological activity testing and development of the antibodies.

Dr. Wenxiang Zhao, founder and CEO of Symary Biopharma, stated: “With the development of general AI technology, the predictive accuracy and efficiency of AI models have seen impressively significant improvements. Our collaboration with BioGeometry in antibody humanization confirms the strong capability of GeoBiologics in AI antibody design. Symary Biopharma is thrilled about the opportunity to work in-depth with BioGeometry, expanding the application of AI technology in antibody drug development, and offering more possibilities to address the challenges of human diseases.”

Dr. Jian Tang, founder and CEO of BioGeometry, remarked: “Symary Biopharma has strong independent R&D capabilities in the field of antibody-based BIC/FIC biological new drugs. I believe that through our generative AI technology, from products to services, and joint pipeline development, we can provide an integrated end-to-end solution that will efficiently support Symary Biopharma’s antibody drug R&D process and improve drug development efficiency.”

About BioGeometry

BioGeometry an AI-driven biotech company dedicated to understanding the language of life through generative AI (AIGC), reconstructing the protein drug discovery and design process, and creating programmable proteins. It solves issues related to the traditionally high costs, long cycles, low success rates, and difficult drug targets in large molecule pharmaceuticals, providing innovative drugs to save patients’ lives. Founded in 2022 by Dr. Jian Tang, a renowned scientist in AI4Drug and deep learning on graphs, with Turing Award laureate Yoshua Bengio serving as the chief scientific advisor, the company has built two foundational platforms: an AI-driven large molecule drug design platform and high-throughput wet-lab validation, creating a closed-loop system that empowers partners to achieve precise and efficient large molecule drug design and optimization.

Business Cooperation: bd@biogeom.com
Official Website: www.biogeom.com

About Symary Biopharma

Established in 2019, Symary Biopharma is a high-tech enterprise specializing in the innovative R&D and clinical translation of large molecule biopharmaceuticals. Guided by clinical value, Symary Biopharma utilizes comprehensive platforms for monoclonal antibody discovery, drug screening and identification, and efficacy validation and assessment to develop monoclonal antibodies, bispecific antibodies, ADCs, and antibody fusion proteins in various therapeutic areas. Focused on independent R&D, collaborative development, and licensing of preclinical large molecule biopharmaceuticals, the company emphasizes differentiated pipelines and high-quality delivery. With an efficient R&D team, mature technology platforms, and a continuously enriched product lineup, Symary Biopharma is committed to helping clients rapidly establish innovative drug development pipelines. The company has been recognized as a high-tech enterprise and awarded as a specialized “new, special, and unique” enterprise in Shanghai.

Business Cooperation: bd@xybiotec.com
Official Website: http://symraybio.net/